Relapsing Malaria: A Case Report of Primaquine Resistance.

Relapsing Malaria: A Case Report of Primaquine Resistance.

Dijanic Christopher; Nickerson Jillian; Shakya Sunita; Dijanic Amanda; Fabbri Marilyn

Case reports in infectious diseases

2018

2018

Primaquine (an 8-aminoquinoline malarial therapy) is the only FDA-approved therapy to treat the hypnozoite stage of P. vivax. We think of relapse occurring because of parasitic resistance or poor compliance secondary to drug toxicities. However, in patients with repeated treatment failure, we must consider CYP-450 mutations affecting drug metabolism as an important cause of relapse. A

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

9720823–9720823

2018